Entering text into the input field will update the search result below

Spark Therapeutics on deck for IPO

Jan. 23, 2015 12:21 PM ETRoche Holding AG (RHHBY) StockRHHBYBy: Douglas W. House, SA News Editor
  • Philadelphia, PA-based Spark Therapeutics (NASDAQ:ONCE) is set for its IPO of 5.5M shares of common stock at $15 - 17.
  • The clinical stage gene therapy firm develops treatments for orphan diseases. Its lead product candidate is SPK-RPE65, currently in Phase 3 for the treatment of rare blinding conditions called inherited retinal dystrophies (IRDs) which are caused by mutations in the RPE65 gene. The FDA has designated SPK-RPE65 a Breakthrough Therapy and an Orphan Drug for this indication. The company plans to submit its Biologics License Application (BLA) to the FDA in 2016.
  • It has established human proof-of-concept using gene therapy to express a therapeutic gene in the liver as part of its SPK-FIX program for the potential treatment of hemophilia B, which is caused by a mutation in the Factor IX (FIX) gene. Last month, it entered into a global collaboration with Pfizer to develop and commercialize SPK-FIX.

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG